Although radical re-resection for gallbladder cancer (GBC) has been advocated, the optimal extent of re-resection remains unknown. The current study aimed to assess the impact of common bile duct (CBD) resection on survival among patients undergoing surgery for GBC.Patients undergoing curative-intent surgery for GBC were identified using a multi-institutional cohort of patients. Multivariable Cox-proportional hazards regression was performed to identify risk factors for a poor overall survival (OS).Among the 449 patients identified, 26.9% underwent a concomitant CBD resection. The median number of lymph nodes harvested did not differ based on CBD resection (CBD, 4 [IQR: 2-9] vs. no CBD, 3 [IQR: 1-7], P?=?0.108). While patients who underwent a CBD resection had a worse OS, after adjusting for potential confounders, CBD resection did not impact OS (HR?=?1.40, 95%CI 0.87-2.27, P?=?0.170). Rather, the presence of advanced disease (T3: HR?=?3.11, 95%CI 1.22-7.96, P?=?0.018; T4: HR?=?7.24, 95%CI 1.70-30.85, P?=?0.007) and the presence of disease at the surgical margin (HR?=?2.58, 95%CI 1.26-5.31, P?=?0.010) were predictive of a worse OS.CBD resection did not yield a higher lymph node count and was not associated with an improved survival. Routine CBD excision in the re-resection of GBC is unwarranted and should only be performed selectively. J. Surg. Oncol. 2016;114:176-180. © 2016 Wiley Periodicals, Inc.
View details for DOI 10.1002/jso.24283
View details for PubMedID 27198742